Upconversion nanoparticles loaded with eIF4E siRNA and platinum(IV) prodrug to sensitize platinum based chemotherapy for laryngeal cancer and bioimaging

Bo Teng, Ping'an Ma*, Chang Yu, Xinyang Zhang, Qingjie Feng, Lianji Wen, Chunxia Li, Ziyong Cheng, Dayong Jin, Jun Lin

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Eukaryotic translation initiation factor (eIF) 4E is a valuable marker in cancer prognostics in many human cancers. Silencing eIF4E via delivery of siRNA may be able to overcome chemoresistance. Cisplatin, used as a first-line anti-cancer reagent, has been widely accepted for its great success in clinical applications but it is restricted due to severe side effects such as nephrotoxicity, peripheral neuropathy, and hearing loss. Moreover, platinum drug resistance is a major obstacle to its use. Platinum(iv) prodrugs (denoted as Pt(iv)) which could be reduced to Pt(ii) by various reductants, including mercaptan and glutathione, within cancer cells have very limited toxicity and might overcome platinum resistance because of their chemical inertness. Moreover, combinational therapies that could sensitize the cancer cells to Pt drugs have received great attention nowadays around the world. Here we report a simple and effective upconversion nanoparticle carrier system loaded with both eIF4E siRNA and Pt(iv). We find that this theranostic system could sensitize laryngeal cancer cells to cisplatin based chemotherapy and allow bioimaging both in vitro and in vivo.

Original languageEnglish
Pages (from-to)307-317
Number of pages11
JournalJournal of Materials Chemistry B
Volume5
Issue number2
DOIs
Publication statusPublished - 2017
Externally publishedYes

Fingerprint Dive into the research topics of 'Upconversion nanoparticles loaded with eIF4E siRNA and platinum(IV) prodrug to sensitize platinum based chemotherapy for laryngeal cancer and bioimaging'. Together they form a unique fingerprint.

Cite this